Cancers represent complex ecosystems comprising tumor cells and a multitude of non-
cancerous cells, embedded in an altered extracellular matrix. The tumor microenvironment …

Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis.
Neutrophils are not homogeneous, however, and could play different roles in cancer …

Neutrophils are increasingly recognized as key players in the tumor immune response and
are associated with poor clinical outcomes. Despite recent advances characterizing the …

Neutrophils are the first responders to infection and inflammation and are thus a critical
component of innate immune defense. Understanding the behavior of neutrophils as they …

In recent years, neutrophils have attracted increasing attention because of their cancer-
promoting effects. An elevated neutrophil-to-lymphocyte ratio is considered a prognostic …

The role of B cells in anti-tumour immunity is still debated and, accordingly,
immunotherapies have focused on targeting T and natural killer cells to inhibit tumour …

Neutrophils are the most abundant myeloid cells in human blood and are emerging as
important regulators of cancer. However, their functional importance has often been …

Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote
immunosuppression, tumor growth, and metastasis. Consequently, these cells have …

Cytotoxic T lymphocyte (CTL) responses against tumors are maintained by stem-like
memory cells that self-renew but also give rise to effector-like cells. The latter gradually lose …